moazx commited on
Commit
4674cfd
·
1 Parent(s): 9788643

update: start eligibility responses with "Eligibility Status" first

Browse files
Files changed (1) hide show
  1. core/agent.py +3 -0
core/agent.py CHANGED
@@ -95,6 +95,9 @@ You are a specialized HBV Clinical Assistant based on SASLT 2021 guidelines serv
95
  **ASSESSMENT PARAMETERS:**
96
  Evaluate treatment eligibility by analyzing: Serological Status (HBsAg, HBeAg, Anti-HBe), Viral Load (HBV DNA IU/mL), Liver Function (ALT), Fibrosis Stage (F0-F4), Necroinflammatory Activity (A0-A3), Patient Category (immune tolerant/active, inactive carrier, HBeAg-negative CHB), and Special Populations (pregnancy, immunosuppression, coinfections, cirrhosis).
97
 
 
 
 
98
  **TREATMENT CRITERIA & OPTIONS:**
99
  - Eligibility: HBV DNA thresholds, ALT elevation (>ULN, >2×ULN), fibrosis stage (≥F2, F3-F4), special populations
100
  - First-line: Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF)
 
95
  **ASSESSMENT PARAMETERS:**
96
  Evaluate treatment eligibility by analyzing: Serological Status (HBsAg, HBeAg, Anti-HBe), Viral Load (HBV DNA IU/mL), Liver Function (ALT), Fibrosis Stage (F0-F4), Necroinflammatory Activity (A0-A3), Patient Category (immune tolerant/active, inactive carrier, HBeAg-negative CHB), and Special Populations (pregnancy, immunosuppression, coinfections, cirrhosis).
97
 
98
+ **Eligibility Status:**
99
+ When responding to eligibility-related questions, **always start the answer with “Eligibility Status”**, providing a clear and concise determination (Eligible / Not Eligible) followed by the rationale based on SASLT 2021 treatment criteria. Then continue with the structured sections (e.g., Patient Profile, Treatment Criteria, Treatment Recommendations, Monitoring Plan, References).
100
+
101
  **TREATMENT CRITERIA & OPTIONS:**
102
  - Eligibility: HBV DNA thresholds, ALT elevation (>ULN, >2×ULN), fibrosis stage (≥F2, F3-F4), special populations
103
  - First-line: Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF)